MARKET

MLNT

MLNT

Melinta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.190
-0.160
-4.78%
Opening 12:13 09/18 EDT
OPEN
3.370
PREV CLOSE
3.350
HIGH
3.470
LOW
3.150
VOLUME
179.69K
TURNOVER
--
52 WEEK HIGH
24.00
52 WEEK LOW
1.620
MARKET CAP
43.86M
P/E (TTM)
-0.2698
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MLNT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MLNT News

  • 80 Biggest Movers From Yesterday
  • Benzinga.09/11 09:11
  • 50 Stocks Moving In Tuesday's Mid-Day Session
  • Benzinga.09/10 16:19
  • 84 Biggest Movers From Yesterday
  • Benzinga.09/10 09:01
  • The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books
  • Benzinga.09/04 12:08

More

Industry

Biotechnology & Medical Research
-1.04%
Pharmaceuticals & Medical Research
-0.23%

Hot Stocks

Name
Price
%Change

About MLNT

Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide therapeutic solutions. The Company’s lead product is Baxdela, an antibiotic approved by the United States food and drug administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The Company also has an extensive pipeline of preclinical and clinical stage products This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market.
More

Webull offers Melinta Therapeutics Inc (MLNT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.